Navigation Links
Array BioPharma To Report Financial Results For The First Quarter Of Fiscal 2014 On October 31, 2013
Date:10/28/2013

BOULDER, Colo., Oct. 28, 2013 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the first quarter of fiscal 2014 and hold a conference call to discuss those results on Thursday, October 31, 2013.  Ron Squarer, Chief Executive Officer and Michael Carruthers, Chief Financial Officer will lead the call.

(Logo: http://photos.prnewswire.com/prnh/20121029/LA02195LOGO)Conference Call InformationDate: Thursday, October 31, 2013Time: 9:00 a.m. eastern timeToll-Free: (877) 261-8990Toll: (847) 619-6441Pass Code: 35902809Webcast, including Replay and Conference Call Slides:
http://investor.arraybiopharma.com/phoenix.zhtml?c=123810&p=irol-irhomeAbout Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Array is evolving into a late-stage development company and currently expects significant progress toward generating data to support our upcoming Phase 3 / pivotal trial decisions.
Novartis began Phase 3 trials evaluating Array-invented MEK162 in patients with NRAS-mutant melanoma in July 2013 and in patients with BRAF-mutant melanoma in October 2013.  In addition, Array began a Phase 3 trial evaluating MEK162 in patients with low-grade serous ovarian cancer under the license agreement with Novartis in June 2013.  AstraZeneca began a pivotal trial with Array-invented selumetinib in patients with thyroid cancer in May 2013 and began a Phase 3 trial in patients with non-small cell lung cancer in October 2013.  Two other wholly-owned drugs, ARRY-520 and ARRY-614, are also approaching Phase 3 or pivotal trial decisions which are expected by the end of 2013.  For more information on Array, please go to www.arraybiopharma.com.CONTACT: Tricia Haugeto Array BioPharma Inc.(303) 386-1193thaugeto@arraybiopharma.com


'/>"/>
SOURCE Array BioPharma Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Arrayit Corporation Announces New Corporate Headquarters in Sunnyvale California
2. ARRAYit Corporation Receives $104,000 Purchase Order from the University of California
3. ARRAYit Corporation Ships Proprietary Life Sciences Products to Google Inc.
4. ARRAYit Corporation Ships Proprietary Life Sciences Products to Illumina Inc.
5. Gentris Corporation Launches Next Generation Human Transcriptome Array
6. Genentech Purchases Arrayit Technology
7. Arrayit on Major Fundraising Drive
8. Arrayit Corporation Holds Successful Meeting with DHK Medical Products CEO
9. Sequenom And CombiMatrix Announce Collaboration Agreement To Market Chromosomal Microarray Analysis For Prenatal Testing
10. Array BioPharma To Report Financial Results For The Fourth Quarter And Full Year Of Fiscal 2013 On August 7, 2013
11. Array Biopharma To Report Top-line Results From ARRY-502 Asthma Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: ... and sells medical devices and wearable sleep respiratory products ... cooperation agreement with Hongyuan Supply Chain Management Co., Ltd. ... 20, 2016, to develop Dehaier,s new Internet medical technology ... will leverage Hongyuan Supply Chain,s sales platform to reach ...
(Date:6/24/2016)... According to a new market ... Needles, Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, ... of Purchase (Retail, Non-Retail) - Trends & Global Forecasts ... market for the forecast period of 2016 to 2021. ... by 2021 from USD 1.65 Billion in 2016, growing ...
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has dedicated ... has implemented orthobiologic procedures as a method for treating his patients. The procedure ... doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of ... of the latter, setting the bar too high can result in disappointment, perhaps even ... progress toward their goal. , Research from PsychTests.com reveals that behind ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are ... for this recognition are considered among the top 2 percent of lawyers practicing within ... of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, ...
Breaking Medicine News(10 mins):